Section 280E — Cannabis Business Tax Deductions Prohibited
26 U.S.C. § 280E is perhaps the single most financially punishing provision of the Internal Revenue Code for any legal industry. It provides that no deduction or credit is allowed for any amount paid or incurred in carrying on a trade or business that consists of trafficking in controlled substances (within the meaning of Schedule I or II of the Controlled Substances Act) which is prohibited by federal law or the law of any state in which the trade or business is conducted. Because cannabis (marijuana) remains a Schedule I controlled substance under federal law — regardless of state legalization — every state-licensed cannabis dispensary, cultivator, manufacturer, and delivery service is engaged in "trafficking" for § 280E purposes. This means cannabis businesses cannot deduct ordinary business expenses — rent, payroll, utilities, marketing, insurance, professional services — that any other business deducts routinely. They can only deduct the cost of goods sold (COGS) — the direct cost of the product itself. Effective federal tax rates for cannabis businesses often run 40–80% of gross profit, compared to 21% for other C corporations. The provision has become one of the most contested issues in cannabis policy reform and is a central driver of the cannabis industry's advocacy for federal rescheduling. For the broader federal policy on cannabis, see Federal Cannabis Policy.
Current Law (2026)
| Parameter | Value |
|---|---|
| Governing provision | 26 U.S.C. § 280E |
| What is disallowed | ALL deductions and credits for businesses engaged in trafficking Schedule I or II controlled substances |
| Cannabis status | Schedule I controlled substance under the Controlled Substances Act — subject to § 280E |
| What IS deductible | Cost of goods sold (COGS) — direct costs allocated to product production under § 471 inventorying rules |
| Effective tax rate impact | Federal taxes on 40–80% of gross profit rather than net income; effectively taxes gross margin, not net profit |
| State conformity | Most states with legal cannabis markets have decoupled from § 280E — state income tax systems allow full deductions |
| DEA rescheduling proposal | As of April 2026: DEA proposed moving cannabis to Schedule III; if finalized, § 280E would no longer apply |
| Applicable entities | All entity types — C corps, S corps, partnerships, LLCs, sole proprietors — all disallowed from deductions |
Legal Authority
- 26 U.S.C. § 280E — No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted
- 21 U.S.C. § 812 — The Controlled Substances Act Schedule I: cannabis (marijuana) is classified as Schedule I (high abuse potential, no accepted medical use, lack of accepted safety for use under medical supervision); this classification is the operative trigger for § 280E
- 26 U.S.C. § 471 — Inventories (COGS): the only tax deductions available to cannabis businesses come through proper allocation of costs to inventory/COGS — this requires careful application of § 471 uniform capitalization rules to identify which costs attach to the product and are recoverable as cost of goods sold
History and Purpose
§ 280E was enacted in 1982 in direct response to Jeffrey Edmondson v. Commissioner, a Tax Court case in which a Minneapolis drug dealer successfully deducted ordinary business expenses (cost of drugs, packaging, telephone, travel) from his illegal drug trafficking income. Congress was outraged — it had no intent to allow drug traffickers to reduce their taxes using normal business deductions — and enacted § 280E to prohibit deductions for businesses trafficking in Schedule I or II substances. The provision was designed for illegal drug dealers, not for state-licensed, state-regulated, tax-paying businesses operating in the open. But Congress never updated it as cannabis legalization expanded — as of April 2026, 24 states and DC have legalized recreational cannabis and 38 states have medical cannabis programs, yet all licensed businesses in those states remain fully subject to § 280E.
How It Works
The math is stark. A cannabis retailer pays $400,000 in wholesale cost for product and earns $1,000,000 in retail sales — its other expenses ($150,000 payroll, $60,000 rent, $30,000 utilities, $20,000 marketing, $40,000 compliance/legal) are completely non-deductible under § 280E. Taxable income: $600,000. At the 21% C corp rate, that's $126,000 in federal tax. A conventional retailer with identical economics would deduct all expenses and pay tax on roughly $300,000 net income — $63,000 in tax. The cannabis business pays twice as much despite the same cash profit. The only carve-out is cost of goods sold: cannabis businesses work aggressively with tax lawyers to maximize what costs can be capitalized into COGS under § 471. For cultivators and manufacturers this includes direct labor, seeds, nutrients, growing media, packaging, and allocated overhead — costs that attach to the product itself. For retailers COGS is primarily the wholesale cost of purchased inventory. Stretching COGS definitions too far (folding in general administrative or selling expenses) invites IRS audit and adjustment.
Some operators try to mitigate § 280E by structuring their businesses to separate "plant-touching" operations (cultivation, manufacturing, retail sale — all subject to § 280E) from ancillary services like management, IP licensing, or consulting that aren't themselves trafficking in cannabis. The ancillary entities can potentially deduct their expenses. The IRS challenges these structures aggressively under the "economic substance" doctrine, arguing that what looks like two businesses is effectively one. On the state side, most legal cannabis states have decoupled their income taxes from § 280E — California, Colorado, and Illinois allow full deductions for state purposes — creating a complex combined effective rate where federal taxes are crushing but state taxes are closer to normal. The IRS has also significantly increased audit activity for cannabis businesses, focusing on COGS classification, separate entity structure legitimacy, and income reporting (cannabis businesses are cash-intensive, adding audit scrutiny).
How It Affects You
If you own or operate a cannabis business (dispensary, cultivator, manufacturer): § 280E is your largest financial challenge besides capital access. You are effectively being taxed on gross margin rather than net income. Hire a CPA with specialized cannabis tax expertise to maximize your § 471 COGS allocation — every dollar properly moved from non-deductible SG&A into deductible COGS saves 21+ cents in federal tax. Consider whether your entity structure can separate truly ancillary functions (management company, IP holding company) from plant-touching operations, but get qualified legal advice before doing so — the IRS scrutinizes these arrangements heavily. Maintain meticulous records of all cost allocations.
If you're an investor in cannabis companies: § 280E creates a structural financial disadvantage for all plant-touching cannabis companies relative to other industries. This is factored into valuations — cannabis retailers trade at lower multiples than comparable conventional retailers precisely because their effective tax rates are much higher. Federal rescheduling to Schedule III (or descheduling) would immediately and dramatically improve the financial position of cannabis operators — § 280E would no longer apply, deductions would be restored, and the industry's tax burden would normalize. Monitor DEA rescheduling proceedings carefully.
If you're a state cannabis regulator or policymaker: § 280E is a federal constraint that state law cannot fix — your ability to help the cannabis industry is limited to state tax decoupling (which most legal states have done). Businesses in your state that are paying enormous federal taxes despite compliance with state law are facing a real economic hardship. Advocating for federal rescheduling or legislative amendment of § 280E is the only path to comprehensive relief.
If you're a cannabis consumer: § 280E is one reason cannabis prices at licensed dispensaries remain high — the tax burden on operators is ultimately passed through to consumers in pricing. This is one economic reason why illicit market cannabis continues to undercut legal market pricing in many states; illegal operators don't pay taxes at all.
State Variations
State cannabis tax treatment varies:
- States with full § 280E decoupling (CA, CO, IL, OR, WA, NJ, and others): cannabis businesses can deduct all ordinary business expenses for state income tax purposes
- States without decoupling: follow federal treatment — § 280E applies to state taxes as well (increasingly rare as more states explicitly decouple)
- States with additional cannabis-specific taxes: many states impose excise taxes on cannabis sales (typically 10–37% of retail price), cultivation taxes (per pound or per ounce), and/or transfer taxes, stacked on top of the general income tax burden created by § 280E
Pending Legislation / Regulatory Action
- DEA Rescheduling Proposal (2024): Following a Department of Health and Human Services review, the DEA proposed moving cannabis from Schedule I to Schedule III. If finalized, § 280E would no longer apply because § 280E only prohibits deductions for trafficking Schedule I and II substances — Schedule III is not covered. This would be the most significant federal cannabis tax change in history without requiring Congressional action.
- SAFE Banking Act: Repeated legislation to allow cannabis businesses access to banking services (currently denied because banks fear federal law violations) — does not address § 280E directly but is often paired with tax reform discussions.
- Small Business Tax Equity Act: Legislation to specifically amend § 280E to exclude state-legal cannabis businesses has been introduced in multiple Congresses. As of April 2026, no bill has passed.
- Cannabis Administration and Opportunity Act (CAOA): Comprehensive federal legalization bill that would deschedule cannabis entirely — § 280E would not apply to a descheduled substance. Introduced in the Senate; not passed.
Recent Developments
- DEA rescheduling to Schedule III: proposed 2024, status uncertain as of April 2026: The DEA's August 2024 proposal to move cannabis from Schedule I to Schedule III — following a formal HHS recommendation — was the most significant potential § 280E development in decades. If finalized, § 280E would immediately stop applying to cannabis businesses (the statute only covers Schedule I and II). Cannabis stocks surged 20–40% on the announcement. However, the DEA's administrative law judge hearing process and the January 2025 presidential transition slowed the proceeding. The Trump administration's DEA leadership signaled mixed signals — some statements supportive of keeping the process moving, others suggesting the proposal might be withdrawn or substantially delayed. As of April 2026, the rescheduling rule had not been finalized, and the cannabis industry continued operating under § 280E.
- IRS audit activity intensified as industry scaled: As the cannabis industry grew to a multi-billion dollar legal market, IRS audit focus on cannabis businesses increased substantially between 2022 and 2025. Key audit issues: whether separate entity structures (management companies, IP licensors) genuinely separate plant-touching from non-plant-touching activities; COGS allocation under § 471; and whether gross income was fully reported by cash-intensive operators. The Harborside case (Patients Mutual Assistance Collective Corp. v. Commissioner, Tax Court 2021) established important precedents for COGS calculation methodology — the Tax Court allowed some costs beyond direct cost of goods but disallowed general administrative and selling expenses.
- Most large cannabis states decoupled from § 280E (2020–2025): California (2022), Illinois, Colorado, New Jersey, Michigan, and other major legal cannabis markets enacted legislation allowing full state income tax deductions for cannabis businesses, explicitly decoupling from the federal § 280E prohibition. This means licensed operators in these states pay ordinary state income tax rates on net income while still paying federal tax on gross margin. The combined effective rate is lower than federal rates alone, but still far above what non-cannabis businesses pay.
- Legislative reform blocked despite bipartisan interest: Multiple § 280E reform bills — the Small Business Tax Equity Act and provisions in the Cannabis Administration and Opportunity Act — were introduced in the 118th and 119th Congresses. Neither advanced in the Senate. The primary obstacle: federal cannabis reform is entangled with criminal justice, banking, and social equity debates that make standalone tax relief politically difficult to package, even when individual members from both parties support it.